User login
We appreciate Dr. Nasrallah referencing our work to assert that “most SGAs are similar to FGAs.” (Current Psychiatry, Comments & Controversies, October 2013, p. 39-40; http://bit.ly/177QOy6). What we actually found in our 20031 and 20112 meta-analyses was that “some antipsychotics are more efficacious than others,” and the first-generation antipsychotic vs second-generation antipsychotic distinction is not very useful clinically.3 These findings have repeatedly been replicated.3
John M. Davis, MD
Professor
Department of Psychiatry
University of Illinois at Chicago
Chicago, Illinois
Ira D. Glick, MD
Professor Emeritus of Psychiatry and Behavioral Sciences
Department of Psychiatry
Stanford University School of Medicine
Stanford, California
1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564.
2. Glick ID, Correll CU, Altamura C, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medication for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011;72(12):1616-1627.
3. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60733-3/abstract. Published June 27, 2013. Accessed November 15, 2013.
We appreciate Dr. Nasrallah referencing our work to assert that “most SGAs are similar to FGAs.” (Current Psychiatry, Comments & Controversies, October 2013, p. 39-40; http://bit.ly/177QOy6). What we actually found in our 20031 and 20112 meta-analyses was that “some antipsychotics are more efficacious than others,” and the first-generation antipsychotic vs second-generation antipsychotic distinction is not very useful clinically.3 These findings have repeatedly been replicated.3
John M. Davis, MD
Professor
Department of Psychiatry
University of Illinois at Chicago
Chicago, Illinois
Ira D. Glick, MD
Professor Emeritus of Psychiatry and Behavioral Sciences
Department of Psychiatry
Stanford University School of Medicine
Stanford, California
We appreciate Dr. Nasrallah referencing our work to assert that “most SGAs are similar to FGAs.” (Current Psychiatry, Comments & Controversies, October 2013, p. 39-40; http://bit.ly/177QOy6). What we actually found in our 20031 and 20112 meta-analyses was that “some antipsychotics are more efficacious than others,” and the first-generation antipsychotic vs second-generation antipsychotic distinction is not very useful clinically.3 These findings have repeatedly been replicated.3
John M. Davis, MD
Professor
Department of Psychiatry
University of Illinois at Chicago
Chicago, Illinois
Ira D. Glick, MD
Professor Emeritus of Psychiatry and Behavioral Sciences
Department of Psychiatry
Stanford University School of Medicine
Stanford, California
1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564.
2. Glick ID, Correll CU, Altamura C, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medication for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011;72(12):1616-1627.
3. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60733-3/abstract. Published June 27, 2013. Accessed November 15, 2013.
1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564.
2. Glick ID, Correll CU, Altamura C, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medication for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011;72(12):1616-1627.
3. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60733-3/abstract. Published June 27, 2013. Accessed November 15, 2013.